// App-Quantinova.ai

260 : Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis

Researchers

Presenter

  • Helena Marzo-Ortega

Principal Investigators

  • Atul Deodhar

  • Corinne Miceli-Richard

  • Xenofon Baraliakos

  • Dafna D Gladman

  • Ruvie Martin

  • Jorge Safi

  • Brian Porter

  • Abhijit Shete

Medical Centers

  • NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, UNITED KINGDOM

  • Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

  • Institut Pasteur, APHP Hôpital Cochin, Paris, FRANCE

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

  • Division of Gastroenterology, Mount Sinai Hospital, Toronto, Ontario, Canada

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

Locations

  • United Kingdom

  • United States

  • France

  • Germany

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Ophthalmology (OP)

Disease

  • Ankylosing spondylitis

  • Uveitis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01649375

  • NCT02008916]

Sponsors

  • Janssen and Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved